Oryzon Genomics SA

As of June 30, 2026, Oryzon Genomics SA carries a market capitalization of 247.01M, placing it among publicly traded companies globally. Its enterprise value stands at 238.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oryzon Genomics SA's next confirmed earnings release is scheduled for October 22, 2026.

As of June 30, 2026, Oryzon Genomics SA has 79.89M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Oryzon Genomics SA maintains a current ratio of 1.60, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.87, indicating elevated leverage, while an interest coverage ratio of -32.28 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Oryzon Genomics SA posted a negative return on equity (ROE) of -1.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.38, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 46.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Oryzon Genomics SA recorded an income tax benefit of -3.48M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -5.40M and -1.93M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Oryzon Genomics SA's stock has declined approximately 22.27% over the past 52 weeks. The 50-day moving average sits at 2.74, while the 200-day moving average is 2.92.

Over the twelve months ended June 30, 2026, Oryzon Genomics SA generated - - in revenue and converted that into -1.93M in net income, yielding earnings per share of -0.03. EBITDA reached -8.81M, while operating income came in at -8.81M.

As of June 30, 2026, Oryzon Genomics SA holds 14.69M in cash and equivalents against 5.83M in total debt, resulting in a net debt position of -8.85M. Total book value stands at 119.70M, with working capital of 6.37M providing operational flexibility.

As of June 30, 2026, Oryzon Genomics SA has an Altman Z-Score of 4.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.